This 12-week open-label, prospective study evaluated the efficacy of combining liraglutide (1.2 mg/day subcutaneously) with metformin (1000 mg twice daily) in 40 obese, non-diabetic women with PCOS who had previously lost less than 5% body weight on metformin monotherapy. Participants were randomized into three groups: metformin alone (MET), liraglutide alone